NCT02385240View on ClinicalTrials.gov

Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea

PHASE3CompletedINTERVENTIONAL

Enrollment

552

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Rosacea

Interventions

DRUG

Brimonidine Topical Gel, 0.33 percent (Perrigo)

DRUG

Brimonidine Topical Gel, 0.33 percent (Reference)

DRUG

Placebo gel

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Padagis LLC

INDUSTRY